{
    "clinical_study": {
        "@rank": "8059", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This multi-center, observational study will evaluate the treatment patterns in clinical\n      practice, efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid\n      arthritis who have had an inadequate response (or were intolerant to) treatment with\n      non-biological DMARDs or with one biological agent. Data will be collected from each\n      eligible patient initiated on RoActemra/Actemra treatment by their treating physician\n      according to approved label for 6 months from start of treatment."
        }, 
        "brief_title": "Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis in Australia", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Severe rheumatoid arthritis\n\n          -  Inadequate response (or intolerant) to non-biological DMARDs or one biologic agent\n\n          -  Patients initiating treatment with RoActemra/Actemra on their physician's decision\n             (in accordance with  the local label), including patients who started treatment with\n             RoActemra/Actemra in the 8 weeks prior to the enrolment visit\n\n        Exclusion Criteria:\n\n          -  RoActemra/Actemra treatment more than 8 weeks prior to the enrolment visit\n\n          -  Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use\n\n          -  Enrolled in an ongoing clinical trial and/or treatment with any investigational agent\n             within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer)\n             before starting treatment with RoActemra/Actemra\n\n          -  History of autoimmune disease or any joint inflammatory disease other than rheumatoid\n             arthritis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Rheumatoid arthritis patients treated with tocilizumab"
            }
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01683604", 
            "org_study_id": "ML28144"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Campsie", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2194"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coffs Harbour", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2450"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Lambton", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2305"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woodville", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5011"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3084"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morwell", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3842"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenton Park", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6008"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Australia: National Health and Medical Research Council"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients on RoActemra/Actemra treatment", 
            "safety_issue": "No", 
            "time_frame": "Approximately 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01683604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rates of dose modifications/interruptions", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2.5 years"
            }, 
            {
                "measure": "Clinical/demographic patient characteristics at initiation of RoActemra/Actemra treatment", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2.5 years"
            }, 
            {
                "measure": "Efficacy: Response according to joint count evaluation by DAS28/EULAR/SDAI/CDAI/ACR", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2.5 years"
            }, 
            {
                "measure": "Efficacy: Proportion of patients on RoActemra/Actemra monotherapy", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2.5 years"
            }, 
            {
                "measure": "Laboratory parameters prior to and during infective adverse events and serious adverse events", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2.5 years"
            }, 
            {
                "measure": "Quality of life: HAQ-DI/VAS-Fatigue/FACIT-Fatigue/Patient Global Assessment of disease activity", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}